KIAA0040 Inhibitors
Uncharacterized protein KIAA0040 (KIAA0040) Inhibitors encompass chemical compounds designed to attenuate the functional activity of KIAA0040 by targeting distinct cellular pathways and molecular processes which KIAA0040 is likely to be involved in. Staurosporine, as a potent protein kinase inhibitor, is presumed to impinge on KIAA0040's activity by curtailing the phosphorylation events pivotal to KIAA0040's regulatory functionality. Rapamycin, a specific mTOR inhibitor, could diminish KIAA0040's activity by impeding mTOR-related protein synthesis and autophagy processes, potentially involving KIAA0040 either directly or indirectly. LY 294002, a PI3K antagonist, may reduce KIAA0040's functional activity by attenuating AKT signaling pathways that possibly stabilize or regulate KIAA0040. WZB117, by obstructing GLUT1, potentially curtails glucose uptake, and thereby may hinder KIAA0040's function if it is reliant on glycolytic energy production.
Continuing with this mechanistic inhibition theme, Bafilomycin A1's inhibition of vacuolar H+-ATPases could lead to a functional decline in KIAA0040 if it is connected to lysosomal degradation pathways. Alisertib's impediment of Aurora A kinase function could attenuate KIAA0040 activity if it is tied to cell cycle progression. Inhibition of MEK by PD 0325901, and consequently the MAPK/ERK signaling, could diminish KIAA0040's role in cell growth and differentiation. Similarly, Cyclopamine's suppression of Hedgehog signaling could decrease KIAA0040's activity if it is a part of this pathway. The Hsp90 inhibitor 17-AAG may destabilize KIAA0040 if it is an Hsp90 client protein, while Thapsigargin's disruption of calcium homeostasis could impair KIAA0040's activity in calcium-dependent signaling pathways. The proteasome inhibitor MG-132 could lead to an indirect reduction in KIAA0040's activity by causing the build-up of ubiquitinated proteins that might interfere with KIAA0040-associated processes. Lastly, ZM-447439's inhibition of Aurora B kinase could lead to inhibited KIAA0040 function if it plays a part in mitotic progression, further establishing the intricate network of cellular processes that KIAA0040 inhibitors engage to temper KIAA0040 activity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. Inhibition of various kinases by Staurosporine could reduce phosphorylation events that regulate the functionality of KIAA0040, thereby leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and the complex inhibits the mTOR pathway, which is involved in protein synthesis and autophagy. Through inhibition of mTOR, KIAA0040, which may be involved in these cellular processes, could have its functional activity diminished due to reduced protein synthesis or altered autophagic degradation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a phosphoinositide 3-kinase (PI3K) inhibitor. By inhibiting PI3K, it leads to a reduction in AKT signaling which could affect the stability and activity of KIAA0040 if KIAA0040 is downstream of this pathway. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 is a glucose transporter 1 (GLUT1) inhibitor. Inhibition of GLUT1 leads to decreased glucose uptake, which could impair the glycolytic pathway and energy production. KIAA0040, potentially involved in energy-dependent processes, would thus have diminished functional activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of vacuolar H+-ATPases. By inhibiting these ATPases, it prevents acidification of organelles such as lysosomes, which could lead to the impairment of lysosomal degradation pathways where KIAA0040 may play a role, thus diminishing its functional activity. | ||||||
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora A kinase inhibitor. Aurora A kinase is involved in cell cycle regulation, and its inhibition could affect cell cycle-related functions. If KIAA0040 is implicated in these processes, inhibition of Aurora A kinase could result in diminished KIAA0040 activity. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $94.00 $208.00 | 19 | |
Cyclopamine is a Hedgehog signaling pathway inhibitor. It specifically targets SMO protein. If KIAA0040 is implicated in the Hedgehog pathway, inhibition by Cyclopamine could lead to a decrease in KIAA0040 functional activity. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $67.00 $156.00 | 16 | |
17-AAG is an Hsp90 inhibitor that leads to the degradation of client proteins. If KIAA0040 is an Hsp90 client protein, its stability and function might be compromised upon Hsp90 inhibition, thus indirectly inhibiting KIAA0040 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor that disrupts calcium homeostasis within the endoplasmic reticulum. Disruption of calcium signaling could negatively affect KIAA0040 if it is involved in calcium-dependent signaling pathways, thus reducing its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. Accumulation of these proteins could interfere with cellular processes including those in which KIAA0040 is involved, potentially leading to its functional inhibition. | ||||||